The concept gaining traction in boardrooms and strategy functions is antifragility, a term developed by New York Polytech professor, Nassim Taleb.
It takes business and commercial strategy beyond resilience. Resilient systems survive shocks - antifragile ones get stronger from them. That's the ambition now shaping how the most forward-thinking pharmaceutical organisations are rebuilding their operations.
The pharmaceutical industry is moving from efficiency as strategy to resilience as competitive advantage. That means accepting costs that traditional optimisation logic would classify as waste, taking concepts like redundant capacity, dual sourcing, strategic inventory buffers, geographic diversification and reframing them as structural insurance as opposed to overheads.
This is sometimes described as regenerative organisation: building on optimised foundations to create something richer, more dynamic, and more durable. In pharma, where the stakes of failure include patient harm, regulatory sanction, and reputational collapse, the argument is especially compelling.
Indiana's pharmaceutical cluster is one of the clearest expressions of this logic in action. The state is home to Eli Lilly's global headquarters, a multi-billion-dollar manufacturing expansion programme driven in large part by GLP-1 demand, and a growing ecosystem of CDMOs, CROs, specialist suppliers, and contract manufacturers. The cluster isn't just a concentration of assets; it's a working model of what resilience-by-design looks like at regional scale.
Here are five ways this transformation is showing up in practice, what each means commercially, and what each demands from a talent strategy perspective.
Concentrating pharmaceutical manufacturing in one or two low-cost global locations makes compelling sense on a spreadsheet. It concentrates risk with equal efficiency.
The BIOSECURE Act has added legislative weight to what was already a commercial imperative. Geographically distributed manufacturing clusters are the structural response: a deliberate rebalancing of the efficiency-versus-resilience equation.
But the benefits of clustering go well beyond risk mitigation. Clusters create ecosystems of supplier networks, shared talent pools connected to local universities, regulatory familiarity, and the kind of institutional knowledge that builds when an industry concentrates in a place across decades. Proximity to talent, embedded market relationships, regulatory confidence, tighter logistics infrastructure, and political stability are all being priced into location decisions in a way they weren't when arbitrage was the dominant logic.
Indianapolis and Indiana: the most significant example in US life sciences
Indiana is the most dramatic example of successful pharmaceutical cluster development in the United States. Eli Lilly's Indianapolis headquarters anchors an ecosystem that extends across the state, from Bloomington to Lebanon to the rapidly developing Lebanon Innovation District, where Lilly's new manufacturing campus represents one of the largest single life sciences capital investments in American history.
The Indianapolis–Carmel–Anderson metropolitan area provides the talent draw and the workforce infrastructure. The I-69 growth corridor connects advanced manufacturing operations across Madison, Hamilton, and surrounding counties, giving companies access to commuter labour pools and lower operating costs than urban Indianapolis while staying within reach of the metro ecosystem.
The cluster isn't close ended either. The balance matters. When you concentrate too tightly a cluster becomes an echo chamber. Indiana's model works because it combines genuine geographic distribution with shared infrastructure: Ivy Tech, Purdue Polytechnic, and local CTE programmes feeding early-career pipelines; regional employers cross-pollinating talent; and a growing CDMO and supplier base that reduces dependence on distant, geopolitically exposed supply chains.
Companies investing in Indiana's cluster are not just competing with each other for talent. They're competing with Lilly itself, with the CDMOs Lilly contracts, and with the broader advanced manufacturing sector that is simultaneously expanding across the region. Understanding that competitive landscape, and building a talent strategy that accounts for it, is not optional for organisations trying to build long-term capability here.
The cluster model is a long-term bet. The organisations winning the talent competition in Indiana right now are the ones building pipelines through Ivy Tech partnerships, CTE engagement, and structured apprenticeships. The region's workforce is there. Accessing it requires understanding of the channels, the motivators and the ever-changing political landscape tied to employer perception and corporate strategy.
The GLP-1 boom has been a wake-up call for the pharmaceutical industry. Demand for semaglutide and tirzepatide exploded faster than any forecast predicted. The efficiency driven injectable fill-finish capacity model couldn't absorb it. Patients went without. The shortages made front pages. The lesson was painful and visible: optimise too far and you build a system with no ability to respond when the product works better than expected.
The response is deliberate investment in manufacturing capacity that looks uncommitted: flexible production lines capable of switching between products and modalities, sterile fill-finish assets with headroom built in by design, platform technologies that aren't locked to a single molecule or format. This is the organisational equivalent of strategic slack with redundancy built intentionally, not tolerated reluctantly.
Manufacturing assets in this model are more than production tools. They are insurance policies that boards are beginning to value explicitly as operational resilience becomes a factor in investor conversations and regulatory confidence assessments. The capacity you didn't use last quarter is the capacity that saves your commercial programme next quarter.
Attracting and retaining multi-skilled talent will be key
Flexible manufacturing infrastructure requires people who can operate across it. Multiskilled maintenance technicians, automation and controls specialists, and process engineers who understand both the science and the operational constraints of multi-product environments. Harba's Anderson data shows this gap: multiskilled maintenance technicians are among the most constrained profiles in the region, with active competition from higher-paying markets and an ageing skilled trades population creating pressure from both ends.
Building flexible manufacturing infrastructure and then staffing it with single-skill specialists defeats the purpose. The talent investment has to match the operational ambition.
Make institutional knowledge a long-term strategy
The contract-to-permanent shift is accelerating in pharma. During optimisation cycles, companies leaned on contract resource for flexibility. Now, as they build long-term manufacturing infrastructure for facilities intended to run for decades, the calculation has changed. Retaining institutional knowledge in multiskilled technical roles is becoming a strategic priority, not just a HR challenge. The organisations building permanent capability now will have a structural advantage that temporary resourcing cannot replicate.
Cell and gene therapies, radioligand therapies, and next-generation biologics are moving through clinical development faster than the manufacturing infrastructure was built to support. The result is a significant compression in the time between 'this works in Phase 2' and 'we need commercial supply.' Every week of delay in a technology transfer is a week of delayed revenue. At scale, that can easily represent hundreds of millions of dollars.
The most forward-thinking organisations are responding by treating technology transfer as a commercial function, not a technical afterthought. They're investing in MSAT teams whose explicit purpose is making transfers faster and more reliable. They're designing processes with transferability in mind from the beginning: building in the documentation standards, platform choices, and analytical methods that make handovers clean rather than chaotic.
The CDMO model has matured considerably, with more pharmaceutical companies manufacturing through contract organisations. That has increased the volume and complexity of transfers happening simultaneously across the industry, and dramatically raised the premium on people who can manage them well. Pipeline value is now partly a manufacturing question. If you can transfer faster, you realise revenue sooner, your pipeline is worth more, and the cost of capital is lower.
Indianapolis as a case study
Indiana's CDMO ecosystem creates a dense network of technology transfer activity within a relatively compact geography. The proximity of development and manufacturing organisations in the Indianapolis corridor is itself a structural advantage: faster handovers, easier communication, shared regulatory relationships, and the ability to move people between organisations when transfer expertise is needed.
The companies building modular, reconfigurable manufacturing structures rather than fixed hierarchies locked to specific molecules, will be better positioned to absorb the next wave of pipeline compression. That architectural choice requires people who think the same way: cross-functional, adaptive, and commercially oriented. Building that capability takes time. Starting the search when a transfer programme is already in crisis is already too late.
For most of the last two decades, sourcing decisions for active pharmaceutical ingredients were fundamentally commercial. Which supplier offered the best price? Which geography offered the most cost arbitrage? The consistent answer was to consolidate into fewer suppliers, larger orders, lower unit costs. COVID exposed what that logic had built. A supply chain optimised for efficiency had quietly concentrated its dependencies into a small number of suppliers across a small number of countries. When disruption came, there was no alternative route and no buffer.
The BIOSECURE Act has layered a legislative dimension onto what was already a commercial imperative. Raw material security is no longer a supply chain strategy - it’s a geopolitical concern. The decision of where to source an API now carries regulatory, national security, and reputational weight simultaneously.
Dual sourcing is becoming a standard procurement requirement, while creating strategic safety stocks and systematically eliminated under just-in-time logic are being prioritised.
Indiana's position as a pharmaceutical manufacturing hub includes growing proximity to domestic API suppliers and excipient manufacturers along the I-69 corridor and broader Midwest industrial base. As companies actively reduce dependence on distant, geopolitically exposed supply chains, location decisions are increasingly favouring clusters where domestic upstream supply ecosystems already exist or are being deliberately built. Indianapolis sits well in that geography and is attracting the supplier investment that reinforces it.
The workforce implications of raw material security are among the least-discussed but most immediate in the industry. The industry needs supplier quality engineers who understand both the commercial and regulatory dimensions of vendor qualification. Procurement specialists who can navigate compliance requirements alongside contract negotiations. Vendor audit professionals with the technical depth to assess a foreign manufacturing facility against FDA expectations.
These are not generalist roles - they’re highly specific, increasingly central to manufacturing continuity, and in genuine short supply. Companies that outsourced or hollowed out their quality and procurement infrastructure during the optimisation era are now facing the cost of rebuilding it in a market where the competition for the same profiles has intensified significantly.
The employer brand challenge
Raw material security is also an employer brand challenge. The supplier quality and procurement functions are not historically glamorous career destinations in pharma. Making them visible, valued, and well-compensated - and communicating that clearly to the talent market - is part of what it means to compete seriously in this space.
For most of pharma's modern history, manufacturing was a downstream question. Scientists discovered the drug. Clinicians tested it. Then often deep in Phase 3, sometimes post-approval someone asked: can we actually make this at commercial scale, reliably, and in a form the FDA will approve?
The industry has paid an enormous price for that sequencing. Several early CAR-T programmes with extraordinary clinical results failed commercially not because the science didn't work, but because the manufacturing did. Low yields, batch inconsistency, process variability that meant the product from one batch wasn't reliably the same as the product from the next. Not clinical failures. Manufacturing failures that could have been anticipated years earlier if the question had been asked sooner.
CMC strategy is now a board-level conversation at leading organisations, particularly in cell and gene therapy where the manufacturing process and the product are effectively inseparable. Platform technologies with proven manufacturing track records are being chosen at molecule selection stage. CDMOs with strong development-to-commercial continuity are commanding premium market positioning because they eliminate transfer risk and compress time to revenue.
This represents a fundamental philosophical shift: the recognition that manufacturing is not downstream of the science, it’s the science, at a certain stage. The molecule and the process that makes it reliably are co-created, not sequential. That changes how organisations are structured, where capital is allocated, what kinds of people are hired and when.
Indianapolis in context
For Indiana manufacturing infrastructure is scaling rapidly alongside growing development activity. This convergence of science and manufacturing is creating an urgent and specific hiring challenge. The companies building out cell and gene therapy capabilities, scaling GLP-1 production, or advancing new modalities through development in and around Indianapolis need people who hold both dimensions in mind simultaneously. That talent doesn't exist in large numbers. It has to be identified, approached, and retained with deliberate intent.
How it relates to talent
When manufacturing thinking enters the development process at Phase 1, you need a different kind of person earlier in the programme. Process development scientists who can think simultaneously about molecular behaviour and commercial-scale production. CMC specialists who hold the regulatory framework and the operational reality in mind at the same time. People who sit comfortably at the intersection of science, engineering, and compliance.
These are not abundant profiles. The traditional pharma career path kept development scientists and manufacturing engineers in largely separate tracks, often in entirely separate organisations. The integrated model requires people who have crossed that boundary, through experience, deliberate development, or exposure to the CDMO model where those boundaries have always been more porous. Finding those people, and finding them early enough in a programme is a form of commercial readiness.
Food for thought
The further downstream you leave the manufacturing question, the more expensive it becomes to answer. The same is true of the talent question. The organisations that wait until a programme is in Phase 3 to build the CMC and process development capability they need are already behind. Pipeline value, increasingly, is partly a talent question.
What's striking when you lay these transformations alongside each other is that they are all expressions of the same underlying change in values. Every one of them involves accepting a cost that the optimisation era would have classified as waste. Every one of them is the industry buying back the insurance it spent twenty years cancelling.
The optimisation era asked: what can we remove?
The resilience era asks: what do we need to never lose?
Those are opposite questions. And answering the second one is the transformation pharma is currently in the middle of. Indianapolis and the Indiana life sciences corridor are not observers of that transformation. They are an active, central part of it.
In every case, it is also a talent transformation. You cannot build resilient supply chains, flexible manufacturing infrastructure, faster technology transfer capability, or earlier commercial readiness without the people who know how to do it. And those people - validation specialists, GMP professionals, MSAT engineers, supplier quality leads, CMC programme managers - are not sitting in a pipeline waiting to be hired. They are embedded, specialised, and in demand across every part of this expanding industry.
The organisations that will win the next decade in pharmaceutical manufacturing are not just the ones investing in the right infrastructure. They are the ones who understand that their talent strategy is their infrastructure strategy and act on that understanding before the need becomes urgent.